Operating Segments

6 Months Ended

12 Months Ended

Jun. 30, 2016

Dec. 31, 2015

Operating Segments [Abstract]

Operating Segments

Note 9. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended   June 30,
	2016			2015
Contract/Grant Revenue
Vaccines/BioDefense	$	3,160,050		$	1,099,827
BioTherapeutics		-			-
Total	$	3,160,050		$	1,099,827
Income (Loss) from Operations
Vaccines/BioDefense	$	734,120		$	302,531
BioTherapeutics		(668,260	)		(1,383,167	)
Corporate		(1,075,818	)		(954,115	)
Total	$	(1,009,958	)	$	(2,034,751	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	10,041		$	9,941
BioTherapeutics		10,564			49,866
Corporate		2,223			1,924
Total	$	22,828		$	61,731
Other Income (Expense), Net
Corporate	$	917,183		$	(1,942,943	)
Share-Based Compensation
Vaccines/BioDefense	$	24,223		$	19,344
BioTherapeutics		30,985			30,179
Corporate		145,065			87,640
Total	$	200,273		$	137,163

	Six Months Ended   June 30,
	2016			2015
Contract/Grant Revenue
Vaccines/BioDefense	$	5,791,037		$	1,902,141
BioTherapeutics		-			13,972
Total	$	5,791,037		$	1,916,113
Income (Loss) from Operations
Vaccines/BioDefense	$	1,052,111		$	387,212
BioTherapeutics		(1,914,682	)		(2,148,043	)
Corporate		(2,053,092	)		(1,832,187	)
Total	$	(2,915,663	)	$	(3,593,018	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	20,060		$	19,727
BioTherapeutics		20,996			98,240
Corporate		4,380			3,690
Total	$	45,436		$	121,657
Other Income (Expense), Net
Corporate	$	1,673,455		$	(4,953,998	)
Share-Based Compensation
Vaccines/BioDefense	$	52,229		$	43,936
BioTherapeutics		65,817			59,435
Corporate		218,638			175,817
Total	$	336,684		$	279,188

	As of  June 30, 2016		As of  December 31,  2015
Identifiable Assets
Vaccines/BioDefense	$	1,921,812	$	2,123,676
BioTherapeutics		63,836		76,183
Corporate		3,430,399		5,187,263
Total	$	5,416,047	$	7,387,122

Note 11. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	For the Years Ended December 31,
	2015			2014
Revenues
Vaccines/BioDefense	$	8,754,418		$	6,756,388
BioTherapeutics		13,972			286,628
Total	$	8,768,390		$	7,043,016
Income (Loss) from Operations
Vaccines/BioDefense	$	1,263,709		$	807,164
BioTherapeutics		(4,487,988	)		(7,674,381	)
Corporate		(3,885,997	)		(3,894,132	)
Total	$	(7,110,276	)	$	(10,761,349	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	39,925		$	39,625
BioTherapeutics		199,661			199,196
Corporate		7,872			6,966
Total	$	247,458		$	245,787
Other Income (Expense), Net
Corporate	$	(1,209,887	)	$	3,437,505
Share-Based Compensation
Vaccines/BioDefense	$	111,960		$	114,920
BioTherapeutics		148,244			193,926
Corporate		394,277			411,304
Total	$	654,481		$	720,150

	As of December 31,
	2015		2014
Identifiable Assets
Vaccines/BioDefense	$	2,123,676	$	1,025,220
BioTherapeutics		76,183		204,308
Corporate		5,187,263		5,724,720
Total	$	7,387,122	$	6,954,248